Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy.
Section of Pathological Anatomy, United Hospital, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy.
Immunotherapy. 2019 Dec;11(17):1507-1521. doi: 10.2217/imt-2019-0115. Epub 2019 Oct 30.
Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.
转移性肾细胞癌的治疗方法随着新的治疗药物的出现而得到了丰富。新的靶向药物和免疫检查点抑制剂联合治疗策略以及免疫检查点抑制剂联合治疗的应用已明确证明了对患者预后和其他临床结局的显著改善。由于有多种治疗方法可供选择，因此在临床实践中，我们可能会面临选择困难的问题。我们总结了当前关于各种治疗方法的知识，重点介绍了可能有助于临床医生做出决策的标准。
